Funding
T-Therapeutics raises $133M Series B for bispecific TCR pipeline
Key Facts
Signal Type
Funding
Industry
Biotech
Companies
T-Therapeutics, Eli Lilly, Johnson & Johnson, Sanofi, Merck KGaA
Date
T-Therapeutics, a Cambridge, England-based biotech, raised a $133M Series B to advance its TCR-CD3 bispecific pipeline. The round was co-led by Advent Life Sciences and British Business Bank, with participation from Eli Lilly, Johnson & Johnson Innovation, Merck KGaA, Sanofi, Samsara BioCapital, Sofinnova Partners, and F-Prime.
The company is progressing TTX-008, an oncology TCR-CD3 bispecific, through IND-enabling studies, with TTX-018, an immunology program, less than a year behind. It also appointed Kirsty Crame, M.D., as chief development officer.
Sales teams targeting biotech and clinical development services should track T-Therapeutics. The company is shifting from discovery into development, with a new CDO responsible for translational and clinical execution.
Its Optimus platform generates fully human TCRs against previously undruggable targets, and management says TCRs open up around 20 times more targets than antibody-based therapies.
The round validates investor appetite for TCR-based therapeutics, with Big Pharma venture arms from Lilly, J&J, Merck KGaA, and Sanofi participating.
Watch for IND filing milestones and the start of first-in-human trials for TTX-008. The appointment of Kirsty Crame signals an imminent push into clinical execution.
Also watch whether T-Therapeutics seeks partnerships or additional services as it scales from discovery to clinical-stage operations.
Source:
Fierce BiotechGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
